medicationPrescription only (US)Approved by the FDA (Pradaxa) as a direct thrombin inhibitor for stroke prevention in nonvalvular atrial fibrillation and for treatment/prevention of venous thromboembolismCarries a boxed warning about increased risk of thrombotic events after premature discontinuation and about spinal/epidural hematoma risk with neuraxial anesthesia
DabigatranBenefits, Dosage & Interactions
Also known as: Pradaxa
Dabigatran, marketed under the brand name Pradaxa, is an anticoagulant medication. It belongs to a class of drugs known as direct thrombin inhibitors. It is typically taken in the morning. The reported plasma half-life is about 12 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 3 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
3 human randomized trials and regulatory approval on file.
Plasma half-life
12–14 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The pivotal RE-LY trial compared dabigatran 110 mg and 150 mg twice daily against warfarin; ablation-related trials used the 150 mg twice-daily dose[1][2][3]
Reported for Dabigatran in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Dabigatran entry is written from. Each number matches an inline marker above.
- [1]Dabigatran versus warfarin in patients with atrial fibrillationConnolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A · The New England Journal of Medicine · 2009 · Peer-reviewed · PMID 19717844
- [2]Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial FibrillationCalkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH · The New England Journal of Medicine · 2017 · Peer-reviewed · PMID 28317415
- [3]A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillationNin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M · Pacing and Clinical Electrophysiology · 2013 · Peer-reviewed · PMID 23121681
How to track Dabigatran doses
Tracking Dabigatran well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Dabigatran with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Dabigatran through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 12 h, effects and timing shifts show up over days rather than instantly. Review Dabigatran alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Dabigatran dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Dabigatran?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Dabigatran, marketed under the brand name Pradaxa, is an anticoagulant medication. It belongs to a class of drugs known as direct thrombin inhibitors. Its primary function is to prevent the formation of blood clots, which can lead to serious conditions such as stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). It is typically prescribed to individuals with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism, for the treatment of DVT and PE, and for the prevention of recurrent DVT and PE after initial therapy. Dabigatran is taken orally as a capsule. Unlike older anticoagulants like warfarin, dabigatran does not require routine blood monitoring, which can simplify its use for patients. (NIH ODS, DrugBank)
What does the research say about Dabigatran?
Tap a section to expand.
Dabigatran etexilate is a prodrug that is converted in the body to its active form, dabigatran. Dabigatran is a direct thrombin inhibitor. Thrombin (Factor IIa) is a key enzyme in the coagulation cascade, playing a central role in the formation of blood clots. Specifically, thrombin converts fibrinogen to fibrin, which then forms the meshwork of a blood clot, and also activates other clotting factors and platelets. By directly binding to and inhibiting thrombin, dabigatran prevents the formation of fibrin and, consequently, the development of blood clots. This action occurs independently of Antithrombin III, distinguishing it from indirect thrombin inhibitors like heparin. The inhibition of thrombin also reduces platelet aggregation and activation. This targeted mechanism provides effective anticoagulation with a predictable pharmacokinetic profile. (DrugBank, EMA SmPC)
Source for this section: Sources for How does Dabigatran work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefits of dabigatran stem from its anticoagulant properties. It is widely used for:
* **Reduction of Stroke and Systemic Embolism Risk in Non-Valvular Atrial Fibrillation:** For individuals with non-valvular atrial fibrillation, dabigatran significantly lowers the risk of stroke and systemic embolism, which are serious complications of the condition. (NIH ODS)
* **Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE):** Dabigatran is effective in treating existing DVT and PE, helping to resolve current clots and prevent their growth. (NIH ODS)
* **Prevention of Recurrent DVT and PE:** Following initial therapy for DVT and PE, dabigatran is used to prevent these conditions from recurring, offering long-term protection. (NIH ODS)
* **Prophylaxis of DVT and PE After Orthopedic Surgery:** In some cases, dabigatran may be used to prevent blood clots after major orthopedic surgeries, such as hip or knee replacement surgery. (EMA SmPC)
Its predictable anticoagulant effect and lack of need for routine blood tests (unlike warfarin) can improve patient convenience and adherence. (MedlinePlus)
Clinical trials have established the efficacy and safety of dabigatran. The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, a landmark study, compared dabigatran with warfarin in patients with atrial fibrillation. This study demonstrated that dabigatran was non-inferior to warfarin for the prevention of stroke and systemic embolism, and the higher dose (150 mg twice daily) was superior to warfarin. Additionally, dabigatran was associated with a lower rate of intracranial hemorrhage compared to warfarin. (Cochrane)
Another significant trial, RE-COVER, evaluated dabigatran for the treatment of acute DVT and PE, finding it to be as effective as warfarin for these indications. Subsequent studies, such as RE-MEDY and RE-SONATE, further supported its use for the long-term prevention of recurrent VTE. These studies consistently highlight dabigatran's predictable anticoagulation profile and its role as an effective alternative to vitamin K antagonists. (DrugBank, EMA SmPC)
Like all medications, dabigatran can cause side effects. The most common and significant side effect is bleeding, given its anticoagulant nature. Bleeding can range from minor events, such as nosebleeds or easy bruising, to serious and life-threatening bleeding episodes, including gastrointestinal bleeding or intracranial hemorrhage. Seek immediate medical attention if you experience severe or uncontrolled bleeding.
Other common side effects include:
* Indigestion (dyspepsia)
* Stomach pain
* Nausea
* Diarrhea
* Heartburn
Less common but serious side effects can include allergic reactions (rash, itching, swelling, severe dizziness, trouble breathing). If you experience any severe or unusual symptoms, contact your healthcare provider immediately. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Dabigatran carries several important warnings. It increases the risk of bleeding, which can be severe and even fatal. Individuals at higher risk of bleeding, such as those with active bleeding, severe kidney impairment, or certain other medical conditions, should use dabigatran with extreme caution or not at all. There is an increased risk of thrombotic events (such as stroke) if dabigatran is prematurely discontinued. Therefore, patients should not stop taking dabigatran without consulting their doctor. For patients undergoing spinal or epidural procedures, there is a risk of epidural or spinal hematoma, which can result in long-term or permanent paralysis. This risk is increased with concomitant use of other drugs affecting hemostasis, traumatic or repeated epidural punctures, or in patients with an indwelling epidural catheter. Dabigatran capsules should be swallowed whole; they should not be broken, chewed, or opened, as this can increase absorption and the risk of bleeding. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Dabigatran is contraindicated in individuals with active pathological bleeding. This includes, but is not limited to, gastrointestinal bleeding, intracranial hemorrhage, or recent significant trauma. It is also contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min for certain indications, or less than 15 mL/min overall, depending on regional guidelines and specific indication), as dabigatran is primarily excreted by the kidneys. Patients with mechanical prosthetic heart valves are not recommended to use dabigatran as it has been associated with an increased risk of thromboembolic events and bleeding compared to warfarin in this population. Hypersensitivity to dabigatran or any component of the formulation is also a contraindication. Care should be exercised in patients with hepatic impairment. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Combining dabigatran with other medications that affect blood clotting can significantly increase the risk of bleeding. These include:
* **Other anticoagulants:** Such as warfarin, heparin, rivaroxaban, apixaban, or enoxaparin.
* **Antiplatelet agents:** Such as aspirin, clopidogrel, ticagrelor, or prasugrel.
* **Nonsteroidal anti-inflammatory drugs (NSAIDs):** Such as ibuprofen, naproxen, or diclofenac, especially chronic use, can increase gastrointestinal bleeding risk.
* **Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs):** These antidepressants can increase the risk of bleeding.
Certain medications can affect the metabolism and plasma concentrations of dabigatran, potentially increasing its effects and bleeding risk:
* **P-glycoprotein (P-gp) inhibitors:** Such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, or clarithromycin. Concomitant use with strong P-gp inhibitors is generally not recommended or requires dose adjustment.
Conversely, P-gp inducers, such as rifampicin, can decrease dabigatran concentrations and reduce its effectiveness. Always inform your healthcare provider about all medications, supplements, and herbal products you are taking. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Dabigatran is typically taken orally, usually twice daily, in the morning and evening, with or without food. It is important to take the capsules whole and not to break, chew, or open them. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. Patients should follow the specific dosing instructions provided by their licensed clinician. The exact dose and timing must be user-directed and set by a licensed clinician to ensure efficacy and minimize risk.
Source for this section: Sources for When should you take Dabigatran?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Dabigatran?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
| Omega-3 (Fish Oil) | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source pending | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Fish Oil (High EPA) | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source pending | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Krill Oil | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source pending | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Curcumin | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source pending | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Vitamin E | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source pending | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Serrapeptase | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source pending | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Bromelain | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source pending | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Vitamin K1 | Caution | Compound pairConfidence: theoretical | Vitamin K reverses vitamin K antagonist activity and shifts INR.Source pending | Keep vitamin K intake consistent; do not start or stop supplementation without INR monitoring. |
| Vitamin K2 | Caution | Compound pairConfidence: theoretical | Vitamin K2 can shift INR on warfarin.Source pending | Discuss with prescribing clinician before adding K2. |
Frequently asked questions about Dabigatran
Dabigatran is a medication. It is also known as Pradaxa. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Dabigatran is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Dabigatran, it is typically taken in the morning and its approximate half-life is 12 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Dabigatran carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
As a medication, Dabigatran can overlap with other supplements, prescription medicines, hormones and peptides. Because Dabigatran is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 12 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Dabigatran with no sign-up.
Whether Dabigatran fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Dabigatran. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 12 hours, once-daily dosing is the usual pattern for Dabigatran. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 12 hours, a single missed dose of Dabigatran usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Dabigatran the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Dabigatran?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Dabigatran versus warfarin in patients with atrial fibrillation(opens PubMed in a new tab)N Engl J Med · 2009 · PMID 19717844 · https://pubmed.ncbi.nlm.nih.gov/19717844/
- 2.The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.(opens PubMed in a new tab)British journal of clinical pharmacology · 2007 · PMID 17506785 · https://pubmed.ncbi.nlm.nih.gov/17506785/
- 3.Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation(opens PubMed in a new tab)N Engl J Med · 2017 · PMID 28317415 · https://pubmed.ncbi.nlm.nih.gov/28317415/
- 4.Dabigatran versus warfarin in patients with mechanical heart valves(opens PubMed in a new tab)N Engl J Med · 2013 · PMID 23991661 · https://pubmed.ncbi.nlm.nih.gov/23991661/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 216210(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/216210
Verify at
Publisher search links for Dabigatran. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Dabigatran?
Plain-text summary, safe to quote verbatim:
Dabigatran, marketed under the brand name Pradaxa, is an anticoagulant medication. It belongs to a class of drugs known as direct thrombin inhibitors. It is typically taken in the morning. The reported plasma half-life is about 12 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/dabigatran
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Dabigatran — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/dabigatran
What compounds are similar to Dabigatran?
Others in the medication category or studied for the same goals.